What is the price-to-earnings ratio of Idorsia?
The price-earnings ratio of Idorsia is currently 2.03.
Idorsia P/S 2024
Idorsia P/S
2.03
Ticker
IDIA.SW
ISIN
CH0363463438
WKN
A2DTEB
As of Jun 28, 2024, Idorsia's P/S ratio stood at 2.03, a -78.22% change from the 9.32 P/S ratio recorded in the previous year.
The Idorsia P/S history
Idorsia Aktienanalyse
What does Idorsia do?
Idorsia Ltd is a biopharmaceutical company that focuses on the discovery, development, and marketing of innovative therapies for patients. The company is headquartered in Switzerland and was founded in 2017 after being spun off from Actelion Ltd. Idorsia was formed by a team of experienced scientists and developers who are known in the industry for their skills and passion for researching new therapies. The company is divided into five main business areas: cardiovascular and respiratory, CNS, immunology, pain, and oncology. Through its research and development activities, Idorsia aims to address medical needs in various areas. The company's innovative therapy approaches have already shown promise and garnered significant attention in the industry. Idorsia receives support from investors and partners. Idorsia's business model is based on an extensive portfolio of already patented and yet-to-be-patented drugs. The company strives to continually optimize and expand its developments within the industry to ultimately treat patients worldwide with its therapies. It collaborates closely with various partners from the biotechnology, pharmaceutical, and other industries to bring products to market and translate scientific knowledge into clinical practice. In the cardiovascular and respiratory field, Idorsia focuses on developing therapies for pulmonary hypertension as well as severe, acute, and chronic cardiovascular diseases. The company's goal is to reduce interventions and interventions for the treatment of these diseases through new treatment options, thus effectively and sustainably improving patients' quality of life. In neurology, Idorsia is involved in research and development of new therapies for disorders of the central nervous system. Here, the company targets the treatment of severe conditions such as epilepsy, sleep disorders, Alzheimer's, and Parkinson's. The research and development activities are carried out in close collaboration with academic research centers and clinics and have already shown success in developing new therapies. In the field of immunology, the company focuses on the development of biological therapies to support the body's immune system in fighting tumors and other severe diseases. Idorsia also focuses on the advancement of personalized medicines tailored to individual patients. In terms of pain, the company focuses on developing therapies that can effectively reduce pain without affecting the patient's perception and quality of life. Idorsia is working on the development of treatment methods that span longer periods and thus serve as an effective alternative to conventional pain therapies. One of the main products introduced by Idorsia is the drug Daridorexant. The drug is a highly selective receptor antagonist developed for the treatment of sleep disorders and other sleep-related conditions. In addition, Idorsia is working on the development of new therapies in the neurology and cardiovascular disease fields. Overall, Idorsia is dedicated to providing patients with valuable and innovative treatment options and, thereby, improving their quality of life. The company relies on scientific research and continuous improvement of its products and services to ensure long-term success in the industry. Idorsia ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/S Details
Decoding Idorsia's P/S Ratio
Idorsia's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.
Year-to-Year Comparison
Comparing Idorsia's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.
Impact on Investments
The P/S ratio is instrumental for investors evaluating Idorsia's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.
Interpreting P/S Ratio Fluctuations
Variations in Idorsia’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.
Frequently Asked Questions about Idorsia Stock
How has the price-earnings ratio of Idorsia changed compared to last year?
The price-to-earnings ratio of Idorsia has increased by -78.22% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of Idorsia high compared to other companies?
Yes, the price-to-earnings ratio of Idorsia is high compared to other companies.
How does an increase in the price-earnings ratio of Idorsia affect the company?
An increase in the price-earnings ratio of Idorsia would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of Idorsia affect the company?
A decrease in the price-earnings ratio of Idorsia would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of Idorsia?
Some factors that influence the price-earnings ratio of Idorsia are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does Idorsia pay?
Over the past 12 months, Idorsia paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Idorsia is expected to pay a dividend of 0 CHF.
What is the dividend yield of Idorsia?
The current dividend yield of Idorsia is .
When does Idorsia pay dividends?
Idorsia pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Idorsia?
Idorsia paid dividends every year for the past 0 years.
What is the dividend of Idorsia?
For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.
In which sector is Idorsia located?
Idorsia is assigned to the 'Health' sector.
Wann musste ich die Aktien von Idorsia kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Idorsia from 6/28/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 6/28/2024.
When did Idorsia pay the last dividend?
The last dividend was paid out on 6/28/2024.
What was the dividend of Idorsia in the year 2023?
In the year 2023, Idorsia distributed 0 CHF as dividends.
In which currency does Idorsia pay out the dividend?
The dividends of Idorsia are distributed in CHF.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Idorsia
Our stock analysis for Idorsia Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Idorsia Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
